BRPI0515553A - formulações lìquidas estáveis de dna de plasmìdeo - Google Patents

formulações lìquidas estáveis de dna de plasmìdeo

Info

Publication number
BRPI0515553A
BRPI0515553A BRPI0515553-3A BRPI0515553A BRPI0515553A BR PI0515553 A BRPI0515553 A BR PI0515553A BR PI0515553 A BRPI0515553 A BR PI0515553A BR PI0515553 A BRPI0515553 A BR PI0515553A
Authority
BR
Brazil
Prior art keywords
plasmid dna
stable
dna
relates
present
Prior art date
Application number
BRPI0515553-3A
Other languages
English (en)
Inventor
Francis Blanches
Michel Coudert
Nicolas Maestrall
Thierry Guillemin
David Gaillac
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/011437 external-priority patent/WO2005026331A2/en
Priority claimed from PCT/EP2005/005213 external-priority patent/WO2005100542A1/en
Application filed by Centelion filed Critical Centelion
Publication of BRPI0515553A publication Critical patent/BRPI0515553A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"FORMULAçõES LìQUIDAS ESTáVEIS DE DNA DE PLASMìDEO". A presente invenção refere-se à formulações líquidas de DNA de plasmídeo que são estáveis e permanecem não degradadas a +4<198>C a temperatura ambiente durante longos períodos de tempo e são, assim, úteis para armazenamento de DNA de plasmídeo que é usado para pesquisa, terapia baseada em plamídeo, tal como vacina de DNA e terapia genética. A presente invenção também refere-se a um método de conservação de DNA de plasmídeo em uma forma estável ao longo do tempo a +4<198>C a temperatura ambiente. A presente invenção também refere-se a composições estáveis líquidas de DNA de plasmídeo para uso em um método de tratamento do corpo de um ser humano ou animal através de terapia baseada em plasmídeo, tal como vacinação com DNA ou terapia genética.
BRPI0515553-3A 2004-09-17 2005-09-19 formulações lìquidas estáveis de dna de plasmìdeo BRPI0515553A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2004/011437 WO2005026331A2 (en) 2003-09-17 2004-09-17 Method of preparation of pharmaceutically grade plasmid dna
PCT/EP2005/005213 WO2005100542A1 (en) 2004-04-19 2005-04-19 Method for purifying plasmid dna
PCT/EP2005/010881 WO2006029908A1 (en) 2004-09-17 2005-09-19 Stable liquid formulations of plasmid dna

Publications (1)

Publication Number Publication Date
BRPI0515553A true BRPI0515553A (pt) 2008-07-29

Family

ID=56290732

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515553-3A BRPI0515553A (pt) 2004-09-17 2005-09-19 formulações lìquidas estáveis de dna de plasmìdeo

Country Status (14)

Country Link
EP (1) EP1791945A1 (pt)
JP (1) JP2008512997A (pt)
KR (1) KR20070058621A (pt)
CN (1) CN101040041A (pt)
AU (1) AU2005284244A1 (pt)
BR (1) BRPI0515553A (pt)
CA (1) CA2579340A1 (pt)
EA (1) EA011554B1 (pt)
IL (1) IL181753A0 (pt)
MX (1) MX2007003214A (pt)
NO (1) NO20071946L (pt)
NZ (1) NZ553914A (pt)
TN (1) TNSN07087A1 (pt)
WO (1) WO2006029908A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2542385C2 (ru) 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
CN104032005B (zh) * 2014-06-12 2015-11-25 成都中创清科医学检验所有限公司 一种pcr测序中间产物的保存剂及保存方法
JP6462723B2 (ja) * 2014-12-29 2019-01-30 株式会社ボナック 核酸分子を安定に含有する組成物
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
RU2628087C1 (ru) * 2016-09-01 2017-08-14 Игорь Валериевич Корниенко Композиция с противомикробным действием для хранения днк или днк-содержащих препаратов (варианты) и её применение
CN106554956A (zh) * 2016-12-07 2017-04-05 安徽智飞龙科马生物制药有限公司 一种产业化制备BCG‑CpG‑DNA的方法
CN110869501B (zh) * 2017-08-01 2023-08-18 深圳华大智造科技股份有限公司 一种高效的内切酶缓冲液体系
AU2018321760A1 (en) * 2017-08-25 2020-02-27 Zoetis Services Llc A nucleic acid probe, a method of immobilizing the nucleic acid to a solid support using UV light, a solid support comprising an immobilized nucleic acid probes, and a test device comprising a solid support
CN111433584B (zh) * 2017-11-22 2023-10-31 拜克门寇尔特公司 稀释剂制备模块和单元
EP3844301A1 (en) * 2018-08-30 2021-07-07 GlaxoSmithKline Intellectual Property Development Ltd Methods of detecting nucleic acid
CN111718961B (zh) * 2019-07-03 2022-02-08 华大青兰生物科技(无锡)有限公司 一种用质粒转化细菌的方法
CN115404232A (zh) * 2021-05-10 2022-11-29 艾棣维欣(苏州)生物制品有限公司 用于提取细菌中质粒dna的方法
WO2023182614A1 (ko) * 2022-03-24 2023-09-28 주식회사 헬릭스미스 플라스미드 dna를 포함하는 액체제형 약제학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
FR2773818B1 (fr) * 1998-01-21 2000-02-18 Pasteur Merieux Serums Vacc Procede et dispositif de lyse de bacteries
WO2001043693A2 (en) * 1999-12-17 2001-06-21 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef

Also Published As

Publication number Publication date
CA2579340A1 (en) 2006-03-23
WO2006029908A1 (en) 2006-03-23
EA011554B1 (ru) 2009-04-28
AU2005284244A1 (en) 2006-03-23
MX2007003214A (es) 2007-10-11
EA200700656A1 (ru) 2007-10-26
NO20071946L (no) 2007-05-29
CN101040041A (zh) 2007-09-19
EP1791945A1 (en) 2007-06-06
JP2008512997A (ja) 2008-05-01
NZ553914A (en) 2009-11-27
KR20070058621A (ko) 2007-06-08
IL181753A0 (en) 2007-07-04
TNSN07087A1 (en) 2008-06-02

Similar Documents

Publication Publication Date Title
BRPI0515553A (pt) formulações lìquidas estáveis de dna de plasmìdeo
Eriksson et al. In VivoGene Transfer to Skin and Wound by Microseeding
BRPI0414867A (pt) pirazolopiridinas e seus análogos
BR112015005674A2 (pt) variantes e métodos de uso de hppd
SG146691A1 (en) Methods of preparing and using stem cell compositions and kits comprising the same
AR061930A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
BR9914939A (pt) Genes e vetores para conferir resistência a herbicidas em plantas
PL1758860T3 (pl) Nasycone i nienasycone 3-pirydylobenzocykloalkilometylo-aminy do leczenia bólów, depresji i stanów lękowych
SG151315A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2004067753A3 (en) Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
PA8609201A1 (es) Piridinonas sustituidas
MX2007007602A (es) Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos.
WO2007084247A3 (en) Stable therapeutic formulations
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
SV2010003596A (es) Sales farmaceuticamente aceptables de (3-{[[3-(6_amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il) propil](3-morfolin-4-ilpropil)amino] metil} fenil) acetato de metilo y sus usos en terapia
WO2007035213A3 (en) Transgenic ungulates expressing ctla4-ig and uses thereof
NO20090410L (no) Aerosolformuleringer for inhalaering av beta-agonister
MX2007013298A (es) Metodo para preparar y usar composiciones de feromona esteroide basadas en agua.
ATE332379T1 (de) Menschliche dnase resistent gegen actininhibitoren
MXPA05003818A (es) Perfilamiento de la expresion genica de muestras ffpe.
RU2013121802A (ru) Профилактический или терапевтический агент для лечения фиброза
ATE552272T1 (de) Myostatin-isoform
PE20080213A1 (es) Derivados del acido fenilacetico como inhibidores de la ciclooxigenasa-2
DK1178960T3 (da) Vitamin D analoger og deres farmaceutiske anvendelse
ATE239749T1 (de) Phosphor-enthaltende dendrimere als transfektionsagente

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.